Cancer of Unknown Primary Site:A Review of 28 Cases and the Efficacy of Cisplatin/Docetaxel Therapy at a Single Institute in Japan
スポンサーリンク
概要
- 論文の詳細を見る
We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.
著者
-
Ennishi Daisuke
Department Of Oncology And Hematology Cancer Institute Hospital
-
Nishimori Hisakazu
Cancer Inst. Hospital Tokyo Jpn
-
Takahashi Shunji
Cancer Inst. Hospital Tokyo Jpn
-
Ennishi Daisuke
Cancer Inst. Hospital Tokyo Jpn
関連論文
- Cancer of Unknown Primary Site:A Review of 28 Cases and the Efficacy of Cisplatin/Docetaxel Therapy at a Single Institute in Japan
- Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer
- Primary Hepatic Low-Grade B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type : A Case Report and Review of the Literature
- The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma : a propensity score matching analysis
- Increased incidence of interstitial pneumonia by CHOP combined with rituximab
- A Case of Acute Promyelocytic Leukemia during Gefitinib Treatment
- Allelic Loss at 1p34,13q12,17p13.3,and 17q21.1 Correlates With Poor Postoperative Prognosis in Breast Cancer
- Correlation of Allelic Loss with Poor Postoperative Survival in Breast Cancer
- PTEN/MMAC1 Mutations in Hepatocellular Carcinomas: Somatic Inactivation of Both Alleles in Tumors
- Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer : cross-resistance to capecitabine
- Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients
- Does Lapatinib, a Small-Molecule Tyrosine Kinase Inhibitor, Constitute a Breakthrough in the Treatment of Breast Cancer?
- Efficacy and Safety of Combined Trastuzumab and Paclitaxel Therapy as a Second-Line Treatment in Women with Metastatic Breast Cancer : A Single Institutional Experience
- High Prevalence of HER-2/neu and p53 Overexpression in Inflammatory Breast Cancer
- Severe Infusion Reaction Induced by Trastuzumab : A Case Report
- Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer
- Pilot study of continuous low-dose 5-fluorouracil and cisplatin (FP regimen) for the treatment of metastatic breast cancer
- Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray
- Amplification, up-regulation and over-expression of DVL-1, the human counterpart of the Drosophila disheveled gene, in primary breast cancers
- High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families
- Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab
- Gene Therapy for Breast Cancer.-Review of Clinical Gene Therapy Trials for Breast Cancer and MDR1 Gene Therapy Trial in Cancer Institute Hospital
- Sentinel Lymph Node Biopsy Using Tin Colloid RI and Blue Dye Method
- Tolerability and Safety of Classic Cyclophosphamide, Methotrexate, and Fluorouracil Treatment in Japanese Patients with Early Breast Cancer
- Report from the second Japanese Urological Association-Japanese Society of Medical Oncology joint conference, 2007 : 'Diagnosis and treatment of urological malignant tumors : How can we promote subspecialists?'
- Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes
- Estrone and 17β-Estradiol Reverse Breast Cancer Resistance Protein-mediated Multidrug Resistance
- Identification and Characterization of a Deletion Mutant of DNA Topoisomerase I mRNA in a Camptothecin-resistant Subline of Human Colon Carcinoma
- Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
- Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells
- Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer
- Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients
- Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane
- Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors